Citadel Advisors’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-6,854,309
Closed -$681M 10285
2019
Q3
$681M Buy
6,854,309
+1,815,193
+36% +$172M 0.32% 33
2019
Q2
$466M Buy
5,039,116
+3,794,539
+305% +$360M 0.21% 44
2019
Q1
$117M Sell
1,244,577
-785,315
-39% -$68.7M 0.06% 304
2018
Q4
$130M Buy
2,029,892
+747,067
+58% +$55.1M 0.07% 239
2018
Q3
$115M Buy
1,282,825
+142,848
+13% +$12.6M 0.05% 364
2018
Q2
$90.5M Buy
1,139,977
+1,096,126
+2,500% +$91M 0.04% 411
2018
Q1
$3.91M Sell
43,851
-3,665,065
-99% -$352M ﹤0.01% 2759
2017
Q4
$387M Buy
+3,708,916
New +$418M 0.24% 47
2017
Q1
Sell
-2,847,235
Closed -$341M 8570
2016
Q4
$330M Buy
2,847,235
+1,632,182
+134% +$182M 0.33% 29
2016
Q3
$127M Buy
1,215,053
+622,075
+105% +$67.3M 0.13% 110
2016
Q2
$58.5M Buy
592,978
+454,003
+327% +$47M 0.07% 275
2016
Q1
$13.9M Sell
138,975
-1,026,027
-88% -$106M 0.02% 975
2015
Q4
$140M Buy
+1,165,002
New +$135M 0.15% 120
2015
Q3
Sell
-1,500
Closed -$186K 9715
2015
Q2
$174K Sell
1,500
-71,011
-98% -$8.12M ﹤0.01% 6495
2015
Q1
$8.36M Sell
72,511
-852,122
-92% -$102M 0.01% 1602
2014
Q4
$103M Buy
924,633
+219,388
+31% +$23.1M 0.1% 194
2014
Q3
$66.8M Sell
705,245
-188,142
-21% -$17M 0.07% 306
2014
Q2
$76.7M Buy
893,387
+54,099
+6% +$4.11M 0.09% 239
2014
Q1
$58.6M Sell
839,288
-66,742
-7% -$5.29M 0.07% 341
2013
Q4
$76.5M Buy
906,030
+216,012
+31% +$17.1M 0.1% 209
2013
Q3
$53.1M Sell
690,018
-891,964
-56% -$62.5M 0.08% 288
2013
Q2
$92.5M Buy
+1,581,982
New +$95.2M 0.16% 114

Other funds holding CELG

Citadel Advisors's CELG Position: Q4 2019 in Review

Citadel Advisors sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 6,854,309 shares — an estimated $681M sold.

Citadel Advisors first reported a position in CELG in Q2 2013 and held it in 22 quarters. The position peaked at $681M in Q3 2019. 4 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

  • Citadel Advisors reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
  • Citadel Advisors sold 6,854,309 Celgene Corp shares in Q4 2019, an estimated $681M.
  • Citadel Advisors first reported a position in Celgene Corp in Q2 2013 and held it in 22 quarters.
  • Citadel Advisors's Celgene Corp position peaked at $681M in Q3 2019.
  • 4 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on Citadel Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.